Thalidomide-induced sinus bradycardia

Annals of Pharmacotherapy

Volumn 37, Issue 7-8, 2003, Pages 1040-1043

  Kaur, Amandeep ^a   Yu, Susan S ^a   Lee, Audrey J ^a,b   Chiao, Teresa B ^a,b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bradycardia; Thalidomide

Indexed keywords

ATENOLOL; THALIDOMIDE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HUMAN; HYPERTENSION; MALE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REFRACTORY ANEMIA; RISK ASSESSMENT; SINUS BRADYCARDIA; TITRIMETRY;

EID: 0037765134     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D003     Document Type: Article

References (19)

1. Ances BM. New concerns about thalidomide. Obstet Gynecol 2002;99:125-8.
2. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother 2002;56:4-12.
3. Package insert. Thalidomid (thalidomide). Warren, New Jersey: Celegene, January 2003.
4. Cavenagh JD, Oakervee H. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol 2003;120:18-26.
5. Singhal S, Mehta J. Thalidomide in cancer: potential uses and limitations. BioDrugs 2001;15:163-72.
6. Raza A, Meyer P, Dutt D, Zorat F, Lisak L, Nascimben F, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958-65.
7. Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 2001;24:87-117.
8. Badros A, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002;112:412-3.
9. Josephson ME, Zimetbaum P. The bradyarrythmias: disorders of sinus node function and AV conduction disturbances. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 15th ed. New York: McGraw Hill, 2001:1283-92.
10. Myerburg RJ, Kloosterman EM, Castellanos A. Recognition, clinical assessment, and management of arrhythmias and conduction disturbances. In: Fuster V, Alexander RW, O'Rourke RA, Roberts R, King SB, Wellens HJJ, eds. Hurse's the heart. 10th ed. New York: McGraw Hill, 2001:855.
11. Katoh T, Kinoshita S, Ueji I, Sasaki Y, Tsujimura Y. Apparent bradycardia-dependent advanced second-degree atrioventricular block. J Electrocardiol 2002;35:153-8.
12. Klein HO, Keren G, Bakst A, Laniado S, Lang R, Kaplinsky E, et al. Transient bradycardia induced by carotid sinus pressure increases outflow obstruction in hypertrophic obstructive cardiomyopathy but not in valvular aortic stenosis. Chest 1998;114:469-76.
13. Wittesjo B, Bjornham A, Eitrem R. Relative bradycardia in infectious diseases. J Infect 1999;39:246-7.
14. Gammage M, Franklyn J. Hypothyroidism, thyroxine treatment, and the heart. Heart 1997;77:189-90.
15. Abouganem D, Taylor AL, Donna E, Baum GL. Extreme bradycardia during sleep apnea caused by myxedema. Arch Intern Med 1987;147:1497-9.
16. Richardson AW, Zimetbaum PJ, Josephson ME. Evaluation of the patient with disturbances of the cardiac rhythm. In: Antman EM, Colucci WS, Gotto AM, Josephson ME, Loscalzo J, Oparil S, et al., eds. Cardiovascular therapeutics. A companion to Braunwald's heart diseases. 2nd ed. Philadelphia: WB Saunders, 2002:391-2.
17. Rajkumar SV, Gertz MA, Lucky MQ, Dispenzieri A, Fonseca R, Geyer SM, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003;17:775-9.
18. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
19. Napoor WN. Syncope and hypotension. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 5th ed. Philadelphia: WB Saunders, 1997:863-76.